Dendritic cell Immunotherapy in HIV
Dr. Miller’s research focuses on the study of myeloid dendritic cell dysregulation during HIV-1 infection and dendritic cell-based immunotherapeutic strategies for HIV–infected individuals. Dr. Miller is involved with pre-clinical investigations of multiple recombinant viral and bacterial vectors for DC-targeting immunotherapies. Furthermore, she evaluates the clinical use of adjuvants for HIV immunotherapies, including toll-like receptor agonists, to enhance innate immune responses during chronic infection and disrupt HIV latency.
Elizabeth Miller, MD. Assistant Professor
1470 Madison Avenue Room 201
New York, NY 10029 | USA